BACKGROUND: Normal aging is associated with a decline in cognitive abilities, particularly in the domains of psychomotor speed and executive functioning. However, 'aging,' per se, is not a cause of cognitive decline but rather a variable that likely captures multiple accumulating biological changes over time that collectively affect mental abilities. Recent work has focused on the role of cerebrovascular disease as one of the biological changes. In the current study, we examined whether lobar microbleeds - magnetic resonance imaging (MRI) signal voids due to hemosiderin deposits secondary to cerebral amyloid angiopathy - are associated with cognitive decline in normal aging. Previous studies that reported a relationship between the presence of lobar microbleeds and decreased cognitive abilities have been primarily cross-sectional. Here, we used a retrospective longitudinal design to examine whether the presence of lobar microbleeds is associated with the rate of cognitive decline among non-demented older adults. METHODS: Participants came from an ongoing longitudinal community-based aging study, in which subjects are evaluated at 18-24 months intervals and received a full medical, neurological, and neuropsychological examination at each of the follow-up visits. Gradient echo MRI scans were available on 197 non-demented participants (mean age: 84.15 ± 5.02 years). Microbleeds were rated visually on axial view and divided into subcortical (basal ganglia, cerebellum) and lobar (frontal, temporal, parietal, occipital lobe) regions, and confirmed with coronal and sagittal views to exclude artifacts. Cognition was assessed with a neuropsychological battery, providing summary scores for memory, language, executive, and visuospatial abilities. Using general estimating equations (GEE), we compared cognition cross-sectionally between individuals with 2 or more (n = 11) and fewer than 2 (n = 186) lobar microbleeds and examined longitudinal cognitive change beginning 9.47 ± 3.13 years before the MRI scan. RESULTS: Subjects with 2 or more lobar microbleeds had worse executive functioning at the visit closest to the MRI scan (β = -0.044; p < 0.001) and had a faster decline in executive function over time (β = -0.072; p = 0.012) than subjects with fewer than 2 lobar microbleeds. The two groups were similar in age at scan date, education, ethnicity, sex distribution, and cognitive performance at first visit. CONCLUSIONS: Lobar microbleeds, a marker of cerebral amyloid angiopathy, are associated with an accelerated rate of executive function decline. The presence of cerebral amyloid angiopathy may be an important source of cognitive decline in aging. Future work should examine how cerebral amyloid angiopathy interacts with neurodegenerative processes, such as Alzheimer's disease.
BACKGROUND: Normal aging is associated with a decline in cognitive abilities, particularly in the domains of psychomotor speed and executive functioning. However, 'aging,' per se, is not a cause of cognitive decline but rather a variable that likely captures multiple accumulating biological changes over time that collectively affect mental abilities. Recent work has focused on the role of cerebrovascular disease as one of the biological changes. In the current study, we examined whether lobar microbleeds - magnetic resonance imaging (MRI) signal voids due to hemosiderin deposits secondary to cerebral amyloid angiopathy - are associated with cognitive decline in normal aging. Previous studies that reported a relationship between the presence of lobar microbleeds and decreased cognitive abilities have been primarily cross-sectional. Here, we used a retrospective longitudinal design to examine whether the presence of lobar microbleeds is associated with the rate of cognitive decline among non-demented older adults. METHODS:Participants came from an ongoing longitudinal community-based aging study, in which subjects are evaluated at 18-24 months intervals and received a full medical, neurological, and neuropsychological examination at each of the follow-up visits. Gradient echo MRI scans were available on 197 non-demented participants (mean age: 84.15 ± 5.02 years). Microbleeds were rated visually on axial view and divided into subcortical (basal ganglia, cerebellum) and lobar (frontal, temporal, parietal, occipital lobe) regions, and confirmed with coronal and sagittal views to exclude artifacts. Cognition was assessed with a neuropsychological battery, providing summary scores for memory, language, executive, and visuospatial abilities. Using general estimating equations (GEE), we compared cognition cross-sectionally between individuals with 2 or more (n = 11) and fewer than 2 (n = 186) lobar microbleeds and examined longitudinal cognitive change beginning 9.47 ± 3.13 years before the MRI scan. RESULTS: Subjects with 2 or more lobar microbleeds had worse executive functioning at the visit closest to the MRI scan (β = -0.044; p < 0.001) and had a faster decline in executive function over time (β = -0.072; p = 0.012) than subjects with fewer than 2 lobar microbleeds. The two groups were similar in age at scan date, education, ethnicity, sex distribution, and cognitive performance at first visit. CONCLUSIONS: Lobar microbleeds, a marker of cerebral amyloid angiopathy, are associated with an accelerated rate of executive function decline. The presence of cerebral amyloid angiopathy may be an important source of cognitive decline in aging. Future work should examine how cerebral amyloid angiopathy interacts with neurodegenerative processes, such as Alzheimer's disease.
Authors: M X Tang; P Cross; H Andrews; D M Jacobs; S Small; K Bell; C Merchant; R Lantigua; R Costa; Y Stern; R Mayeux Journal: Neurology Date: 2001-01-09 Impact factor: 9.910
Authors: Anne F Wiegman; Irene B Meier; Nicole Schupf; Jennifer J Manly; Vanessa A Guzman; Atul Narkhede; Yaakov Stern; Sergi Martinez-Ramirez; Anand Viswanathan; José A Luchsinger; Steven M Greenberg; Richard Mayeux; Adam M Brickman Journal: J Neurol Sci Date: 2014-07-18 Impact factor: 3.181
Authors: David J Werring; Duncan W Frazer; Lucy J Coward; Nick A Losseff; Hilary Watt; Lisa Cipolotti; Martin M Brown; H Rolf Jäger Journal: Brain Date: 2004-07-28 Impact factor: 13.501
Authors: Patrick J Lao; José Gutierrez; David Keator; Batool Rizvi; Arit Banerjee; Kay C Igwe; Krystal K Laing; Mithra Sathishkumar; Fahmida Moni; Howard Andrews; Sharon Krinsky-McHale; Elizabeth Head; Joseph H Lee; Florence Lai; Michael A Yassa; H Diana Rosas; Wayne Silverman; Ira T Lott; Nicole Schupf; Adam M Brickman Journal: Ann Neurol Date: 2020-10-09 Impact factor: 10.422
Authors: Adam M Brickman; Vanessa A Guzman; Miguel Gonzalez-Castellon; Qolamreza Razlighi; Yian Gu; Atul Narkhede; Sarah Janicki; Masanori Ichise; Yaakov Stern; Jennifer J Manly; Nicole Schupf; Randolph S Marshall Journal: Neurosci Lett Date: 2015-03-04 Impact factor: 3.046
Authors: Angel Piriz; Dolly Reyes; Atul Narkhede; Vanessa A Guzman; Fawad Viqar; Irene B Meier; Mariana Budge; Pedro Mena; Stephen Dashnaw; Joseph Lee; Christiane Reitz; Jose Gutierrez; Luis Campos; Martin Medrano; Rafael Lantigua; Richard Mayeux; Adam M Brickman Journal: J Alzheimers Dis Date: 2018 Impact factor: 4.472
Authors: Mafalda Cacciottolo; Amy Christensen; Alexandra Moser; Jiahui Liu; Christian J Pike; Conor Smith; Mary Jo LaDu; Patrick M Sullivan; Todd E Morgan; Egor Dolzhenko; Andreas Charidimou; Lars-Olof Wahlund; Maria Kristofferson Wiberg; Sara Shams; Gloria Chia-Yi Chiang; Caleb E Finch Journal: Neurobiol Aging Date: 2015-10-19 Impact factor: 4.673
Authors: Briana S Last; Maria-José García Rubio; Carolyn W Zhu; Stephanie Cosentino; Jennifer J Manly; Charles DeCarli; Yaakov Stern; Adam M Brickman Journal: Exp Aging Res Date: 2017 Mar-Apr Impact factor: 1.645
Authors: Jie Ding; Sigurður Sigurðsson; Pálmi V Jónsson; Gudny Eiriksdottir; Osorio Meirelles; Olafur Kjartansson; Oscar L Lopez; Mark A van Buchem; Vilmundur Gudnason; Lenore J Launer Journal: Neurology Date: 2017-05-03 Impact factor: 9.910